Business Context and Reporting Period
This Form 6-K filing by GSK plc, dated October 21, 2025, reports on the full results of the pivotal Phase III PIVOT-PO clinical trial for tebipenem HBr. The data was presented at IDWeek 2025. Tebipenem HBr is an investigational oral carbapenem antibiotic developed in collaboration with Spero Therapeutics to treat complicated urinary tract infections (cUTIs), including pyelonephritis.
Key Financial and Operational Metrics
The filing focuses on clinical trial efficacy and safety rather than financial performance. No revenue, profit, cash flow, or debt metrics are provided in this document.
- Primary Endpoint Success: Tebipenem HBr demonstrated non-inferiority to intravenous imipenem-cilastatin.
- Overall Success Rate: 58.5% for tebipenem HBr (261/446 participants) vs. 60.2% for imipenem-cilastatin (291/483 participants).
- Adjusted Treatment Difference: -1.3% (95% CI: -7.5%, 4.8%).
- Clinical Cure Rate: 93.5% for tebipenem HBr vs. 95.2% for imipenem-cilastatin.
- Safety Profile: Generally similar to comparator; most frequent adverse events were mild/moderate diarrhea and headache.
- Market Context: cUTIs result in over $6 billion in annual US healthcare costs.
Material Changes and Developments
The primary material change is the successful completion of the PIVOT-PO trial, which was stopped early for efficacy in May 2025. This represents a significant milestone as it validates the potential for tebipenem HBr to be the first oral carbapenem antibiotic approved for cUTIs in the US, potentially reducing the need for hospital-based intravenous treatments.
Guidance, Outlook, and Risks
- Regulatory Filing: GSK plans to submit data to US regulatory authorities in Q4 2025 as part of a New Drug Application (NDA).
- Strategic Outlook: Approval would add to GSK's anti-infectives portfolio and address antimicrobial resistance (AMR). The asset holds Qualified Infectious Disease Product (QIDP) and Fast Track designations.
- Development Partnership: GSK holds an exclusive license from Spero Therapeutics. Sponsorship of the NDA will transfer from Spero to GSK following this study.
- Risks: Forward-looking statements are subject to risks including regulatory approval uncertainties and clinical trial outcomes, as detailed in GSK's 2024 Form 20-F and Q2 2025 results.
Key Facts for Investor Verification
- Verify the timeline for the Q4 2025 regulatory filing and potential FDA review dates.
- Confirm the commercial terms of the exclusive license agreement with Spero Therapeutics, including royalty structures and milestone payments.
- Assess the competitive landscape for oral antibiotics treating multidrug-resistant cUTIs.
- Monitor the safety data for long-term use, as the trial focused on a 7-10 day treatment course.
- Check for any updates on the BARDA federal funding contract (HHSO100201800015C) supporting development.